CA3011800A1 - Methods for treating cancer - Google Patents

Methods for treating cancer Download PDF

Info

Publication number
CA3011800A1
CA3011800A1 CA3011800A CA3011800A CA3011800A1 CA 3011800 A1 CA3011800 A1 CA 3011800A1 CA 3011800 A CA3011800 A CA 3011800A CA 3011800 A CA3011800 A CA 3011800A CA 3011800 A1 CA3011800 A1 CA 3011800A1
Authority
CA
Canada
Prior art keywords
cancer
compound
formula
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3011800A
Other languages
English (en)
French (fr)
Inventor
Chiang J. Li
Laura BORODYANSKY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Oncology Inc
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Publication of CA3011800A1 publication Critical patent/CA3011800A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3011800A 2016-01-20 2017-01-19 Methods for treating cancer Abandoned CA3011800A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662281004P 2016-01-20 2016-01-20
US62/281,004 2016-01-20
PCT/US2017/014163 WO2017132049A1 (en) 2016-01-20 2017-01-19 Methods for treating cancer

Publications (1)

Publication Number Publication Date
CA3011800A1 true CA3011800A1 (en) 2017-08-03

Family

ID=58737850

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3011800A Abandoned CA3011800A1 (en) 2016-01-20 2017-01-19 Methods for treating cancer

Country Status (7)

Country Link
US (2) US20190076392A1 (enExample)
EP (1) EP3405189A1 (enExample)
JP (1) JP2019506392A (enExample)
CN (1) CN109069469A (enExample)
CA (1) CA3011800A1 (enExample)
TW (1) TW201731500A (enExample)
WO (1) WO2017132049A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736563C (en) 2007-09-10 2016-01-26 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
CN107666906A (zh) * 2015-04-17 2018-02-06 波士顿生物医药有限公司 用于治疗癌症的方法
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
BR112021002630A2 (pt) 2018-08-17 2021-05-11 Ptc Therapeutics, Inc. método para tratar câncer pancreático
EP3865130A4 (en) 2018-10-12 2022-07-20 1Globe Biomedical Co., Ltd. NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-REFRACTORY CANCER
WO2025040685A1 (en) * 2023-08-21 2025-02-27 Abliva Ab Quinones for use in the treatment of red blood cell enzymopathies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736563C (en) 2007-09-10 2016-01-26 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
RU2591823C2 (ru) 2010-03-19 2016-07-20 Бостон Байомедикал, Инк. Новые способы направленного воздействия на раковые стволовые клетки
WO2011116398A1 (en) 2010-03-19 2011-09-22 Boston Biomedical, Inc. Novel compounds and compositions for targeting cancer stem cells
US9150530B2 (en) 2011-03-04 2015-10-06 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
KR20150139955A (ko) * 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
CN107666906A (zh) * 2015-04-17 2018-02-06 波士顿生物医药有限公司 用于治疗癌症的方法
TW201717935A (zh) * 2015-06-03 2017-06-01 波士頓生醫公司 用於治療癌症的組成物和方法

Also Published As

Publication number Publication date
US20190224157A1 (en) 2019-07-25
CN109069469A (zh) 2018-12-21
EP3405189A1 (en) 2018-11-28
TW201731500A (zh) 2017-09-16
US20190076392A1 (en) 2019-03-14
WO2017132049A1 (en) 2017-08-03
JP2019506392A (ja) 2019-03-07

Similar Documents

Publication Publication Date Title
US20190224157A1 (en) Methods for treating cancer
US20180085341A1 (en) Methods for treating cancer
US10646464B2 (en) Methods for treating cancer
US20180250261A1 (en) Method for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
US20180250260A1 (en) Methods for treating cancer
US20250235425A1 (en) New Combination Solution for Treating Chemotherapy Refractory Cancer
CA2983013A1 (en) Methods for treating cancer
HK40048413A (en) New combination solution for treating chemotherapy refractory cancer
EA046190B1 (ru) Новое комбинированное решение для лечения рака, резистентного к химиотерапии
HK40047114A (en) New combination solution for treating chemotherapy refractory cancer

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230419

FZDE Discontinued

Effective date: 20230419